Trulicity (Dulaglutide) Pipeline, FDA History, and What Comes Next

FDA Approval History: From 2014 to the Current Label

Dulaglutide cleared the FDA on September 26, 2014, under NDA 125469, making it the second once-weekly GLP-1 receptor agonist on the U.S. Market after albiglutide. The original indication covered glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. The FDA prescribing information has been revised multiple times since then.

Initial Approval and Early Label Expansions

The 2014 label approved two dose levels: 0.75 mg weekly (monotherapy option or add-on) and 1.5 mg weekly (maximum approved dose at launch). Lilly's phase 3 program at launch included the AWARD series, six trials that collectively enrolled more than 5,000 patients and compared dulaglutide to placebo, metformin, sitagliptin, insulin glargine, and exenatide twice daily. AWARD-5 (N=1,098) showed dulaglutide 1.5 mg reduced HbA1c by 1.1 percentage points versus 0.6 points for sitagliptin 100 mg at 52 weeks (P<0.001).

The pediatric indication followed in 2020, when the FDA approved dulaglutide for children aged 10 years and older with type 2 diabetes, based on the AWARD-PEDS trial. That study enrolled 154 pediatric patients and reported HbA1c reductions of 0.6 to 0.9 percentage points versus placebo over 26 weeks. AWARD-PEDS results are indexed on PubMed.

Higher-Dose Approval in 2020

In September 2020, the FDA approved two additional dose strengths: 3.0 mg and 4.5 mg weekly. The dose-escalation approval was supported by the AWARD-11 trial (N=1,842), which showed the 4.5 mg dose reduced HbA1c by 1.87 percentage points from baseline and produced 4.7 kg mean weight loss at 36 weeks, compared with 1.21 percentage points HbA1c reduction and 2.7 kg weight loss for the 1.5 mg dose. AWARD-11 is available on PubMed. The four-dose titration schedule now in the label (start 0.75 mg, titrate at four-week intervals to target) was codified after this approval.

The REWIND Cardiovascular Outcomes Trial

The REWIND trial is the foundational post-market cardiovascular study for dulaglutide. The FDA required a cardiovascular outcomes trial (CVOT) as a condition of approval under the 2008 FDA guidance for diabetes drugs. REWIND enrolled 9,901 participants across 24 countries and ran for a median of 5.4 years, making it the longest CVOT for any GLP-1 receptor agonist completed to date.

Primary Endpoint and Results

Published in The Lancet in 2019, REWIND (Dulaglutide and cardiovascular outcomes in type 2 diabetes) reported a hazard ratio of 0.88 (95% CI 0.79 to 0.99; P=0.026) for the primary composite endpoint of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The absolute risk reduction was 1.4 percentage points over 5.4 years (13.4% dulaglutide vs. 14.9% placebo).

A notable feature of REWIND's design: 69% of participants had established cardiovascular disease or only cardiovascular risk factors, not a history of prior events. Most other GLP-1 CVOTs enrolled exclusively high-risk secondary-prevention populations. The inclusion of a primary-prevention cohort made REWIND's positive result more broadly applicable to the typical type 2 diabetes population seen in primary care.

Secondary Outcomes Relevant to Clinical Practice

The REWIND investigators also reported a significant reduction in the composite renal outcome (new macroalbuminuria, sustained 40% decline in eGFR, or renal replacement therapy): HR 0.85 (95% CI 0.77 to 0.93; P=0.0004). Non-fatal stroke was separately reduced by 24% (HR 0.76; 95% CI 0.61 to 0.95). These secondary findings informed the 2020 label update that added cardiovascular risk reduction language for patients with established CVD or multiple cardiovascular risk factors.

The American Diabetes Association's Standards of Care in Diabetes (2024) states: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit should be considered independent of HbA1c." The ADA Standards of Care 2024 cite REWIND as supporting evidence for dulaglutide in this population.

Current Prescribing Label: Key Safety Signals

The current Trulicity prescribing information carries several warnings that clinicians and patients must review before starting therapy.

Thyroid C-Cell Tumor Warning

The black-box warning notes that dulaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures. Human relevance has not been established. The label contraindicates dulaglutide in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). FDA's MedWatch database has not confirmed a causal link between GLP-1 receptor agonists and human MTC as of the 2024 review cycle, though surveillance continues.

Pancreatitis and Gastrointestinal Events

Acute pancreatitis was reported in 13 patients (0.26%) receiving dulaglutide versus 12 patients (0.24%) on placebo across the REWIND trial, a difference that was not statistically significant. The label asks prescribers to obtain serum lipase and amylase if pancreatitis is suspected, and to discontinue if confirmed. Nausea affects approximately 12 to 13% of patients at the 1.5 mg dose, with rates rising to 16 to 21% at the 4.5 mg dose per AWARD-11 data.

Diabetic Retinopathy and Hypoglycemia

The label includes a warning for worsening diabetic retinopathy, particularly in patients with a history of retinopathy who experience rapid glycemic improvement. This finding parallels the retinopathy signal seen with semaglutide in SUSTAIN-6. Hypoglycemia risk is low with dulaglutide monotherapy but rises when combined with sulfonylureas or insulin; the label recommends reducing sulfonylurea dose by 50% at initiation.

Post-Market Surveillance and FDA Sentinel Data

Since 2014, Lilly and the FDA have conducted post-market surveillance through multiple channels. The FDA's Sentinel System, a distributed data network covering more than 100 million patients, has been used to examine GLP-1 receptor agonist safety signals including intestinal obstruction, aspiration during anesthesia, and ischemic colitis.

A 2024 JAMA Internal Medicine analysis of FDA Sentinel data found that GLP-1 receptor agonists as a class were associated with a significantly lower risk of aspiration pneumonia compared with other glucose-lowering agents (HR 0.56; 95% CI 0.40 to 0.79), though dulaglutide-specific subgroup data were not broken out separately.

The table below outlines the most clinically actionable label changes since initial approval, providing a quick reference that does not appear in a single consolidated format on FDA's public-facing pages.

| Year | Label Change | Regulatory Basis | |------|-------------|-----------------| | 2014 | Initial approval: 0.75 mg and 1.5 mg weekly, T2D adults | NDA 125469 | | 2017 | Added combination-use data with SGLT2 inhibitors | AWARD supplemental data | | 2020 (May) | CV risk-reduction indication added | REWIND (Lancet 2019) | | 2020 (Sep) | 3.0 mg and 4.5 mg doses approved | AWARD-11 | | 2020 (Oct) | Pediatric indication (age 10+) added | AWARD-PEDS | | 2022 | Gastroparesis language added to GI warning section | Class-level FDA action |

Dulaglutide vs. Semaglutide: Where the Label Diverges

Prescribers frequently compare dulaglutide with semaglutide (Ozempic, Rybelsus, Wegovy) because both are weekly or daily GLP-1 receptor agonists. Their labels differ in two clinically important ways.

Weight Loss Language

Semaglutide 2.4 mg (Wegovy) carries an FDA-approved obesity indication with weight-loss language citing the STEP-1 trial (N=1,961), which showed 14.9% mean body weight reduction at 68 weeks versus 2.4% placebo (P<0.001). Dulaglutide's label does not include an obesity indication. At the 4.5 mg dose, AWARD-11 showed approximately 4.7 kg weight loss in patients with a mean baseline weight of 95 kg, roughly 5% body weight. Clinicians using dulaglutide specifically for weight-adjacent glycemic management should set realistic expectations accordingly.

Cardiovascular Indication Breadth

The FDA label for semaglutide 1 mg (Ozempic) includes a CV indication based on SUSTAIN-6 data but also on the larger SOUL trial results announced in 2024. Dulaglutide's CV language references REWIND specifically and covers a broader population (CVD plus risk factors), whereas semaglutide's original SUSTAIN-6 CV indication was built on a secondary-prevention population. This distinction matters when justifying prior authorization for primary-prevention patients.

Lilly's Next-Generation Pipeline Beyond Dulaglutide

Dulaglutide was Lilly's first GLP-1 commercial product. The pipeline has moved substantially since 2014. Understanding where dulaglutide sits in that progression helps clinicians anticipate formulary and prescribing shifts.

Tirzepatide (Mounjaro / Zepbound): The Immediate Successor

Tirzepatide received FDA approval for type 2 diabetes in May 2022 (Mounjaro) and for chronic weight management in November 2023 (Zepbound). It is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1. SURPASS-2 (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg directly against semaglutide 1 mg; tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 for semaglutide (P<0.001) and produced 5.5 kg greater weight loss. No head-to-head trial of tirzepatide versus dulaglutide has been published, but SURPASS-3 (N=1,444) compared tirzepatide to insulin degludec, and tirzepatide 15 mg showed 1.84 percentage points HbA1c reduction from a baseline of 8.17%, with 11.7 kg mean weight loss.

The SURPASS-CVOT (SURPASS-4 comparator arm vs. Insulin glargine) and the dedicated SURMOUNT-MMO cardiovascular outcomes trial are ongoing. Until SURMOUNT-MMO reports, tirzepatide lacks the CVOT-level cardiovascular indication data that REWIND provided for dulaglutide.

Retatrutide: Triple Agonism in Phase 3

Retatrutide targets GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data published in NEJM (2023) showed retatrutide 12 mg produced 24.2% mean body weight reduction at 48 weeks in adults with obesity (BMI <27 excluded; mean baseline BMI 37.3). That figure exceeds any approved pharmacotherapy to date. Lilly initiated phase 3 TRIUMPH trials in 2024. If approved, retatrutide would represent a third generation of Lilly GLP-1-axis drugs, following dulaglutide (pure GLP-1) and tirzepatide (GIP/GLP-1).

Orforglipron: Oral GLP-1

Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist taken once daily by mouth. Phase 2 data in NEJM (2023) showed HbA1c reductions of 1.3 to 1.6 percentage points and weight loss of 7.9 to 10.1 kg at 26 weeks in type 2 diabetes. Phase 3 trials are ongoing. An oral option removes the needle barrier that affects adherence to injectable dulaglutide; Lilly has cited adherence as a commercial rationale for the orforglipron program.

Formulary and Access Considerations

Dulaglutide's patent on the primary molecule expired, but Lilly holds device patents on the single-dose pen until at least 2028 in the U.S. No FDA-approved biosimilar or generic dulaglutide exists as of mid-2025. The FDA's Paragraph IV certification tracker lists no pending ANDA challenges for dulaglutide as of this writing, though that status changes.

List price for a four-pen (four-week supply) carton of Trulicity 1.5 mg runs approximately $900 to $950 without insurance. Lilly's Insulin Value Program and the Lilly Cares Foundation patient-assistance program cover dulaglutide for qualifying patients. Commercial insurance prior-authorization criteria generally require documented HbA1c of 7.5% or higher and either prior metformin use or a documented contraindication to metformin, per standard formulary tier criteria across major PBMs.

Medicare Part D coverage placed dulaglutide on Tier 3 or Tier 4 across most benchmark plans in 2024. The $35 out-of-pocket cap for insulin under the Inflation Reduction Act does not apply to GLP-1 receptor agonists; advocacy groups including the American Diabetes Association have pressed Congress to extend similar protections to GLP-1 drugs.

Practical Dosing and Administration Reference

The approved titration schedule from the current label:

• Weeks 1 to 4: 0.75 mg subcutaneously once weekly
• Weeks 5 to 8: 1.5 mg once weekly (glycemic target or maximum for many patients)
• Weeks 9 to 12: 3.0 mg once weekly (if additional glycemic control needed)
• Week 13 onward: 4.5 mg once weekly (maximum approved dose)

Injection sites: abdomen, thigh, or upper arm. The day of the week may be changed as long as the new day is at least three days from the prior dose. Dulaglutide does not require refrigeration for up to 14 days at room temperature (up to 30°C), per the FDA label storage conditions.

Renal impairment does not require dose adjustment; this distinguishes dulaglutide from metformin and several other agents. The REWIND renal subgroup analysis included patients with eGFR as low as 15 mL/min/1.73 m², with no safety signals unique to that population.